Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer | Zendy

Suresh S. Ramalingam | Zendy; Fiona Blackhall | Zendy; Maciej Krzakowski | Zendy; Carlos H. Barrios | Zendy; Keunchil Park | Zendy; Isabel Bover | Zendy; Dae Seog Heo | Zendy; Rafael Rosell | Zendy; Denis Talbot | Zendy; Richard C. Frank | Zendy; Stephen P. Letrent | Zendy; Ana RuízGarcía | Zendy; Ian W. Taylor | Zendy; Jane Liang | Zendy; Alicyn Campbell | Zendy; Joseph O’Connell | Zendy; Michael Boyer | Zendy

Open Access

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Author(s) -

Suresh S. Ramalingam,

Fiona Blackhall,

Maciej Krzakowski,

Carlos H. Barrios,

Keunchil Park,

Isabel Bover,

Dae Seog Heo,

Rafael Rosell,

Denis Talbot,

Richard C. Frank,

Stephen P. Letrent,

Ana RuízGarcía,

Ian W. Taylor,

Jane Liang,

Alicyn Campbell,

Joseph O’Connell,

Michael Boyer

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.40.9433

Subject(s) - erlotinib , medicine , kras , epidermal growth factor receptor , lung cancer , erlotinib hydrochloride , hazard ratio , oncology , clinical endpoint , adverse effect , cancer , gastroenterology , randomized controlled trial , pharmacology , colorectal cancer , confidence interval

This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research